US FDA Rejects Sleep Peptide Emideltide Over Safety and Addiction Risks
The US FDA advisory committee has voted against approving the peptide Emideltide as a sleep aid, citing significant safety risks, potential addiction concerns, and a lack of solid scientific evidence regarding its long-term health impacts.
An advisory committee of the US Food and Drug Administration (FDA) has voted against approving Emideltide, a peptide widely marketed as a sleep aid. The decision classifies the supplement as a substance carrying significant safety risks and bans US compounding pharmacies from producing it. This move highlights growing concerns within the medical establishment regarding the lack of solid scientific evidence for its efficacy and, more importantly, its long-term health consequences.
From Deep Sleep Claims to Conflicting Research
Emideltide, also known as DSIP, is a synthetic peptide originally isolated from the blood of rabbits in the 1970s. It is typically administered via injection or nasal spray. According to user claims and online reports, the supplement helps individuals fall asleep faster, extends deep sleep duration, and even induces lucid dreams. However, most of these claims are based on anecdotal evidence rather than large-scale, controlled clinical trials.
Most studies examining Emideltide's impact on sleep are outdated, having been conducted primarily in the 1980s and 1990s, with findings that were mixed and often contradictory. For instance, one small trial found that participants who received an injection of the substance fell asleep faster than the placebo group on the first night, but on the second night, the placebo group fell asleep faster. Another study assessing its efficacy among chronic insomnia sufferers found minimal therapeutic benefit.
The Core Concern: Opioid System Interaction
The primary reason for the FDA committee's rejection lies in significant safety risks. Although the peptide does not bind directly to opioid receptors, evidence indicates it interacts with the brain's opioid system, potentially triggering the release of endorphins. This connection raises severe concerns regarding addiction potential, an area where no studies prove its safety. Furthermore, data on the effects of repeated use are lacking, and some studies have reported side effects such as headaches, nausea, and low blood pressure.
The FDA's decision to keep Emideltide off the approved list sends a critical message to the public: not every supplement marketed as a health solution is safe or effective. The absence of quality research and the presence of potential risks, including addiction, underscore the danger of using unapproved substances.
